77 results about "Genus Bifidobacterium" patented technology

The invention discloses a sodium polyacrylate-grafted and sodium alginate-embedded probiotic microcapsule, which is prepared by carrying out ionic crosslinking and embedding on probiotic with a complex of sodium polyacrylate-grafted sodium alginate and sodium alginate as an inner layer wall material, and coating chitosan on an outer layer. The embedded probiotic is one or more than two of lactobacillus, galactococcus or bifidobacterium; and the sodium polyacrylate is a state-approved food additive, and is safe and nontoxic in embedding. The buffer action on gastric acid caused by the inner layer wall material is increased through a grafting method; reduction of viable count in a gastric juice environment is reduced; meanwhile, the mechanical strength of the microcapsule is enhanced by cross-linking property of the capsule and calcium ions; the viscosity of a wall material solution is lower than that of an existing high polymer material; the preparation difficulty of the microcapsule is reduced; the prepared microcapsule has the functions of resisting gastric juice and accelerating intestinal release; the effective living bacteria count of intestinal tracts can be improved when the microcapsule is applied to embedding the probiotic; and the in-vivo probiotic function is enhanced.

The present invention relates to bifidobacterium breve CCFM1025, its fermented food and application thereof. Bifidobacterium breve CCFM1025 of the present invention can improve the depression-like behavior of depressed mice, increase the levels of 5-hydroxytryptophan, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice, and reduce the levels of 5-hydroxytryptophan in the serum of depressed mice. Corticosterone levels, increased serum 5-hydroxytryptamine levels in depressed mice, improved intestinal flora disturbance in depressed mice, decreased intestinal Veillonellaceae abundance, increased the abundance of Bifidobacteria and Mycoplasmaceae , increase the α-diversity of intestinal flora, reduce the occurrence of inflammatory bowel disease and obesity; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the level of 5-hydroxytryptophan in this cell Secretion, specifically providing precursors for the synthesis of 5-HT in the brain. It has broad application prospects.

This invention relates to the use of a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and / or fat intake.

A method of producing a fermented milk characterized by comprising conducting the fermentation with the use of, as lactic acid bacteria, a bacterium belonging to the genus Bifidobacterium and a bacterium belonging to the genus Lactococcus which has the following mycological properties: (1) such a fermentability that, in the case where the bacterium is cultured in a 10% reduced skim milk medium at a temperature of from 25 to 37 degrees centigrade for 16 hours, the medium is solidified; (2) such an effect of promoting the growth of Bifidobacterium longum that, in the case where the bacterium is cultured together with Bifidobacterium longum in the above-described medium and the pH value attains 4.4 to 4.6, the bifidobacterial count amounts to 5x10<8> CFU / g or more; and (3) such an effect of promoting the storage survival of Bifidobacterium longum that, in the case where the bacterium is cultured together with Bifidobacterium longum in the above-described medium, quenched at the point when the pH value attains 4.4 to 4.6 and then stored at 10 degrees centigrade for 2 weeks, the survival rate of Bifidobacterium longum amounts 30% or more; and a fermented milk produced by this production method.

The invention relates to bifidobacterium animalis and a breeding method and application thereof, and belongs to the technical field of bifidobacterium lactis. According to the bifidobacterium animalisdisclosed by the invention, the strain is bifidobacterium animalis IU100 in the bifidobacterium genus, and the preservation number of the strain is CGMCC (China General Microbiological Culture Collection Center) No. 12942. The bifidobacterium animalis strain is a bifidobacterium strain obtained by continuously researching intestinal floras of the longevous in Bama district in Guangxi of China formany years, selecting elder excrement samples with a high intestinal bifidobacteria quantity and carrying out separation and purification by utilizing a selective culture method. The bifidobacteriumanimalis disclosed by the invention not only can improve intestinal health conditions of populations, but also has a potential effect of improving immunity; and meanwhile, the invention provides a simple and feasible breeding method and application. The breeding method is high in efficiency and low in cost.

A composition and method for the treatment of chronic sinusitis in which a composition containing desirable colonial bacteria is applied externally in the form of either a spray or a flush. The bacteria are selected from the genus Lactobacillus and the genus Bifidobacterium. The selected bacteria are provided in a therapeutically effective amount in a water solution.

The invention relates to bifidobacterium longum subspecies CCFM687, fermented food and application thereof. Bifidobacterium longum infantile subspecies CCFM687 of the present invention can improve the depression-like behavior of depressed mice, improve the levels of 5-hydroxytryptamine, 5-hydroxytryptophan and brain-derived neurotrophic factor in the brain of depressed mice; improve depression Butyric acid content in the gut of mice; lower intestinal abundance of Desulfovibrio spp., increased abundance of Bifidobacterium and S24‑7 families, increased gut microbiota α‑diversity, and improved intestinal Intestinal flora disorder, reduce the occurrence of autism, inflammatory bowel disease, obesity and type I diabetes; increase the mRNA level of tryptophan hydroxylase 1 in simulated enterochromaffin cells, and increase the 5-hydroxychromatin level of the cells The secretion of amino acid provides precursor substances for the synthesis of 5-hydroxytryptamine in the brain. Therefore, it has broad application value.

The present invention relates to a composition comprising Bifidobacterium bacteria for use for reducing intestinal gas production in an individual.

A polysaccharide comprises galactose, glucose, rhamnose and pyruvic acid as constituents, the galactose, glucose and rhamnose being contained at a molar ratio of 4:2:1 and the pyruvic acid being contained in an amount of 4 to 7% by mass. The polysaccharide can be produced by culturing cells of Bifidobacterium longum strain JBL05 (NITE BP-82) under anaerobic conditions.

The invention belongs to the field of biological health care, and particularly relates to lactobacillus paracasei and application thereof in regulating intestinal flora. The lactobacillus paracasei is lactobacillus paracasei (Lactobacillus paracasei) WG-7, and the preservation number of the lactobacillus paracasei WG-7 is CGMCC No.15961. Another purpose of the lactobacillus paracasei is to provide application of the lactobacillus paracasei WG-7 in regulating the intestinal flora, and particularly relates to application of the lactobacillus paracasei WG-7 in preparation of drugs and / or food and / or health care products for regulating the intestinal flora. The lactobacillus paracasei WG-7 can be used for effectively regulating the intestinal flora and promoting positive balance of micro-ecology of an organism, and can be used for effectively increasing the quantity of one or more of bifidobacteria and lactobacillus in intestinal tracts under the condition that the total quantity of the intestinal flora is basically not changed; and the quantity of one or more of escherichia coli and enterococcus in the intestinal tract is reduced.

The present invention addresses the problem of providing an agent for degrading an opioid peptide or a composition for degrading an opioid peptide which requires no restriction on diet, shows no sideeffects even if used regularly and, therefore, can be continuously used free from anxiety. To solve this problem, provided are an agent for degrading an opioid peptide, a composition for degrading anopioid peptide, a medicinal composition for degrading an opioid peptide and a food or beverage composition for degrading an opioid peptide, each comprising, as an active ingredient, a bacterium belonging to the genus Bifidobacterium, a culture of the bacterium and / or treated cells of the bacterium.

This invention relates to the use of a composition comprising a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis (strain) 420 (B420), and one or more prebiotics and / or fibres, for use in increasing lean body mass in a mammal.

Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This may present a risk of a horizontal transfer of functional antibiotic genes. The present invention relates to a method of obtaining novel tetracycline-sensitive strains of the genus of Bifidobacteriacea (Bifidobacterium sp.). In particular, the present invention relates to novel antibiotic-sensitive strains obtained from antibiotic-resistant probiotic strains and the use of such novel strains for the preparation of a food or feed product or a dosage form comprising viable organisms.

The invention relates to probiotic bacterial strains and symbiotic composition containing the same intended for infant food. The present invention relates to a selection of probiotic strains belongingto the genus Bifidobacterium and to a symbiotic composition containing the same, intended for feeding infants.

A red dragon fruit enzyme, preparation method and application thereof relate to the field of health food with health care effects. The red pitaya enzyme in the embodiment of the present invention is mainly prepared from the red pitaya fermentation liquid rich in short-chain fatty acids and functional galacto-oligosaccharides. The microbial combination starter of Fidobacterium, Bacteroides, and Eubacterium is obtained by fermentation and filtration by a three-step directional fermentation method. The pitaya enzyme is easily absorbed by the human body, has comprehensive effects, and has high economic value. The pitaya enzyme of the embodiment of the present invention can be used to regulate the gene expression of gastrointestinal mucosal cells, repair gastrointestinal mucosa, and assist in the treatment of gastric ulcer; it can be used to regulate the intestinal flora environment, relieve bowel movements, and prevent colorectal cancer; Improve the basic metabolism of the human body and have a good hypoglycemic effect.

The present invention provides a shuttle vector for a microorganism of the genus Bifidobacterium (BM) and Escherichia coli having a wide host range and a large copy number in BM and capable of highly expressing a desired protein when used as an expression vector; an expression vector capable of expressing a desired gene in BM by use of the shuttle vector; BM transformed with the expression vector; and an antitumor agent comprising the BM as an active ingredient. The vector comprises a pTB6-derived region portion comprising a replication origin (oriV)-repB region of pTB6 but not comprising MembB, MobA, OrfI, and oriT regions of pTB6 and an Escherichia coli-derived plasmid portion comprising a replication origin (oriC) region of Escherichia coli but having deleted DNA encoding an N-terminal region of an ampicillin resistance gene (ampR) expression product -lactamase, and constitute a shuttle vector for Escherichia coli with a BM having an average copy number of 6 to 30.

The present invention relates to a composition for producing a fermented milk product showing a low degree of post-acidification during storage comprising 1) a starter culture of lactic acid bacteria comprising at least one lactose-deficient Streptococcus thermophilus strain, which is capable of metabolizing a non-lactose carbohydrate, and at least one lactose-deficient Lactobacillus delbrueckiisubsp. bulgaricus strain, which is capable of metabolizing the non-lactose carbohydrate, and 2) a probiotic strain selected from the group consisting of Lactobacillus strain and a Bifidobacterium strain.